Menu
ETF
Annual · values2025202420232022202120202019
Operating Cash Flow-14.83 M USD-2.27 M USD-9.66 M USD-14.86 M USD-8.97 M USD-13.79 M USD-12.59 M USD
Depreciation & Amortization3.58 M USD2.96 M USD2.42 M USD2.26 M USD1.52 M USD1.31 M USD2.64 M USD
Stock-Based Compensation3.14 M USD2.67 M USD5.54 M USD6.61 M USD6.87 M USD9.04 M USD102000 USD
Capital Expenditures83000 USD156000 USD236000 USD115000 USD354000 USD366000 USD389000 USD
Cash Flow from Investing1.28 M USD-2.16 M USD-4.16 M USD-115000 USD-354000 USD-326000 USD-2.09 M USD
Cash Flow from Financing10.26 M USD78000 USD19.76 M USD-1.99 M USD361000 USD50.00 M USD15.95 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-14.91 M USD-2.43 M USD-9.89 M USD-14.97 M USD-9.32 M USD-14.16 M USD-12.98 M USD

Lensar Inc. is renowned for its advancement in femtosecond laser technology, specifically designed for cataract surgery. As a medical technology company, Lensar focuses predominantly on offering innovative solutions that enhance the precision and effectiveness of cataract surgery procedures. Its flagship product, the Lensar Laser System, is engineered to provide surgeons with superior imaging and laser guidance to perform precise cataract surgeries, thereby improving surgical outcomes and patient safety. Lensar operates at the intersection of healthcare and technology, influencing the ophthalmology sector significantly. By providing state-of-the-art laser systems, the company plays a critical role in advancing surgical standards and patient care in the rapidly growing field of eye health. Headquartered in Orlando, Florida, Lensar continues to contribute to medical technology through continuous research and development, reinforcing its position as a key player in promoting cutting-edge surgical solutions globally.